AgingResearch.NewsJoin free

Galimedix Therapeutics

CompanyUnited States

Galimedix Therapeutics develops one asset, in phase 2 (GAL-101 in geographic atrophy of the macula). Mostly small molecule acting on APP and proteostasis; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • GAL-101

    Small molecule amyloid oligomer pan-inhibitor preventing neurotoxic oligomer formation

    Phase 2, Small molecule, APP, Proteostasis, geographic atrophy of the macula

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Similar companies6

Intelligence